SCHEMBL4778418

SCHEMBL4778418

COCCCNC(=O)c1cnn2c(C)c(Cc3ccc(F)c(Cl)c3)c(C)nc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 10/20 0.64
LMNA P02545 9/20 0.64
KDM4E B2RXH2 7/20 0.54
ALDH1A1 P00352 7/20 0.54
HPGD P15428 6/20 0.54
MAPT P10636 4/20 0.54
HSD17B10 Q99714 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
MAPK1 P28482 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
NPSR1 Q6W5P4 4/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
TSHR P16473 2/20 0.49
HTT P42858 2/20 0.49
USP2 O75604 1/20 0.49
ALOX12 P18054 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4779270 0.89 LMNA (0.73) TP53LMNAKDM4EALDH1A1HPGD
SCHEMBL4780215 0.88 KDM4E (0.60) TP53LMNAKDM4EALDH1A1HPGD
SCHEMBL4776282 0.87 TP53 (0.65) TP53LMNAKDM4EALDH1A1HPGD
SCHEMBL4796244 0.86 KDM4E (0.74) TP53LMNAKDM4EALDH1A1HPGD
SCHEMBL4796625 0.85 LMNA (0.76) TP53LMNAKDM4EALDH1A1HPGD
SCHEMBL4725398 0.84 ALDH1A1 (0.73) TP53LMNAKDM4EALDH1A1HPGD
SCHEMBL4776468 0.84 HSD17B10 (0.69) TP53LMNAKDM4EALDH1A1HPGD
SCHEMBL4796367 0.83 KDM4E (0.63) TP53LMNAKDM4EALDH1A1HPGD
SCHEMBL4781087 0.83 TP53 (0.62) TP53LMNAKDM4EALDH1A1HPGD
SCHEMBL4778100 0.83 KDM4E (0.59) TP53LMNAKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221129-A1 New compounds BIOVITRUM AB (PUBL) (SE) 2008-09-11 US claimed
WO-2008003753-A1 PYRAZOLO [1,5-A] PYRIMIDINE ANALOGS FOR USE AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) ACTIVITY BIOVITRUM AB (PUBL) (SE) 2008-01-10 WO claimed
US-20080221129-A1 New compounds BIOVITRUM AB (PUBL) (SE) 2008-09-11 US disclosed
WO-2008003753-A1 PYRAZOLO [1,5-A] PYRIMIDINE ANALOGS FOR USE AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) ACTIVITY BIOVITRUM AB (PUBL) (SE) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221129-A1 New compounds SCD, SCD5, FASN TP53 1572/4885LMNA 2075/4885KDM4E 3813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.